TENET HEALTHCARE CORP Q3 FY2026 earnings call

• Financial Performance: Third quarter net operating revenues reached $5.6 billion with consolidated adjusted EBITDA of $1.355 billion. Adjusted diluted EPS rose 80% to $6.64. Core business adjusted EBITDA margins stood at 21.8%.
• Operational Strategy: Continued execution of the high-acuity strategy yielded strong results, including 12.8% same-store growth in total joint replacements at ASCs. USPI remains the preferred acquirer for assets with a robust pipeline.
• Cost Discipline: Significant progress on efficiency initiatives and disciplined operating expense management contributed to margin strength. AI and technology tools are being adopted to improve cost controls and OR productivity.
• Cash Flow & Capital Return: Generated $1.1 billion in adjusted free cash flow in Q3 ($2.5 billion YTD). Deployed over $1.6 billion for share repurchases YTD. Leverage ratio is 2.11x EBITDA.
• Conifer Transition: Recognized $147 million in non-recurring benefits from timing shifts and early expense reductions related to Conifer transitions. Total expected value from the transaction is approx. 15x 2025 adjusted EBITDA minus NCI.

USPI (U.S. Physician & Surgery): Generated $537 million in adjusted EBITDA, representing a 9% growth over the prior year. Same-facility revenues grew 4.5%, driven by a 6.1% increase in net revenue per case, which offset a 1.5% decline in same-facility case volumes due to the high-acuity strategy. The segment achieved an adjusted EBITDA margin of 39.2%. Hospital Segment: Driven by 3.2% growth in adjusted admissions and healthy patient demand. Revenue per adjusted admission increased slightly by 0.2% YoY. Excluding one-time contract transition benefits, adjusted EBITDA grew 11% YoY. Exchange-related admissions and revenues declined significantly by 18% YoY, though this represented only about 5.5% of consolidated net operating revenues.

• Full Year 2026 Adjusted EBITDA: Raised guidance to a range of $5.05–$5.2 billion, an increase of $195 million (4%) at the midpoint over previous raised guidance. Over 40% of this increase stems from fundamental outperformance.
• Full Year 2026 Revenue: Revised upward to $22.05–$22.45 billion, an increase of $50 million at the midpoint.
• Full Year 2026 Free Cash Flow: Raised to $1.925–$2.155 billion after NCI, an increase of $100 million at the midpoint. This includes ~$150 million in tax payments for the Conifer transaction.
• 2027 Outlook: Excluding the $450 million in one-time Conifer transition benefits expected in 2026, management expects enterprise-wide adjusted EBITDA growth in 2027, assuming current regulatory frameworks remain stable.

• Exchange Headwinds: Payer mix shifts and enrollment declines in health exchanges continue to impact volume, with exchange admissions down 18% YoY.
• Regulatory Uncertainty: Potential impacts from Medicaid work requirements and the finalization of H.R. 1 legislation create uncertainty regarding supplemental Medicaid payments and coverage.
• Uncompensated Care: Slight uptick in unpaid admissions and outpatient visits observed in Q3, correlating with exchange volume reductions.
• Surgical Environment: While performing competitively well, the broader surgical environment is described as not 'gangbusters,' requiring careful management of demand trends.

Q: Analyst asked about commercial pricing sustainability and payer relationships.

A: Management stated commercial renewals remain strong at 3-5%, with >90% contracted for next year. Net revenue per adjusted admission grew 0.2%, driven by favorable pricing mix, partially offset by 1.8% headwind from exchange declines. Conifer's revenue yield capabilities and tech investments support sustained performance despite payer denial activity.

Q: Analyst inquired about the surgical environment outlook and EBITGrowth drivers for 2027.

A: CEO noted the industry surgical backdrop is not 'gangbusters' but Tenet’s high-acuity strategy yields differentiated results. For 2027, excluding the $450M one-time Conifer items, management expects continued EBITDA growth. Confidence is rooted in the diversified platform and ability to manage controllable activities effectively.

Q: Analyst asked about ASC growth engines beyond orthopedics and market valuation context.

A: Management highlighted diversification into urology, general surgery, spine, and advanced robotics as key growth areas. Regarding valuation, CEO emphasized delivering differentiated earnings growth and returning cash via buybacks at attractive multiples. M&A pipeline remains strong, with most deals coming exclusively to USPI rather than competitive processes.

Q: Analyst sought clarification on hospital segment margin trajectory and life cycle.

A: CFO explained that significant efficiency gains have been realized through technology adoption and AI tools, particularly in response to exchange headwinds. While further opportunities exist, the base is now efficient. Management expects to continue dialing operations up or down as needed, with labor and supplier management remaining stable.

Q: Analyst asked about OR productivity dynamics and anesthesia costs amidst longer case times.

A: CEO detailed efforts to maximize fixed OR capacity utilization through analytics-driven scheduling and AI tools for patient outreach to reduce cancellations. Anesthesia costs, previously a negative expenditure line, have stabilized. The company prioritizes in-network anesthesia providers to control costs while managing complex, longer-duration cases efficiently.